PepGenPEPG
About: PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Employees: 81
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1.08% less ownership
Funds ownership: 77.74% [Q3] → 76.65% (-1.08%) [Q4]
3% less funds holding
Funds holding: 62 [Q3] → 60 (-2) [Q4]
56% less capital invested
Capital invested by funds: $217M [Q3] → $94.7M (-$122M) [Q4]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $57K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 108 / 352 met price target | 946%upside $16 | Buy Reiterated | 24 Feb 2025 |
Financial journalist opinion
Based on 22 articles about PEPG published over the past 30 days
